Aquestive Therapeutics

Company snapshot

Acuitas Therapeutics Inc., the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, is a Vancouver-based company collaborating with pharmaceutical and biotech companies, academic researchers, and global health organizations to advance a broad range of medicines for a variety of diseases. Acuitas’s clinically validated LNP technology has enabled two approved pro

• 9 active pipeline program(s) linked via ClinicalTrials.gov.
• 17 US patent(s) indexed to this assignee profile.
• 9 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Aquestive Therapeutics. Not investment advice.

• Peer + 0 momentum

  PTC THERAPEUTICS

  TA overlap score 30.4

Recent activity

Latest pipeline, patent, and corporate events for Aquestive Therapeutics.

1. Jun 8, 2026 Clinical update

   42-1703 — Phase 3

2. Jun 8, 2026 Clinical update

   Riluzole Oral Soluble Film — Phase 2

3. Jun 8, 2026 Clinical update

   Ondansetron (ODFS) — Phase 2

4. Jun 8, 2026 Clinical update

   Diazepam Buccal Film — Phase 2

5. Jun 8, 2026 Clinical update

   Diazepam Buccal Film 12.5 mg — Phase 2

View all clinical trial activity →

• What is Aquestive Therapeutics?

  Aquestive Therapeutics is a pharma organization headquartered in Vancouver, CA. It trades on NYSE under ticker AQST. Primary therapeutic focus areas include Epilepsy, Allergic Reaction, Nausea and Vomiting, Postoperative, Amyotrophic Lateral Sclerosis. NovaPharmaNews links 9 clin

• Is Aquestive Therapeutics publicly traded?

  Yes. Aquestive Therapeutics is listed with ticker AQST on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Aquestive Therapeutics develop or market?

  We link 9 drug profile(s) where Aquestive Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/aquestive-therapeutics#company-drugs.

• What are the latest developments for Aquestive Therapeutics?

  In the last 12 months our linked public records show 9 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does Aquestive Therapeutics focus on?

  Aquestive Therapeutics focuses on Epilepsy, Allergic Reaction, Nausea and Vomiting, Postoperative based on our analysis of their pipeline programs and drug development activities.